Why Opko Health Stock Surged by 33% on Tuesday
Investors were also cheered by a substantial narrowing of the company's net loss. Ditto for the raised full-year revenue guidance.
OPK - OPKO Health, Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$2.87
DETAILS
HIGH:
$4.00
LOW:
$1.60
MEDIAN:
$3.00
CONSENSUS:
$2.87
UPSIDE:
73.94%
Stock News
OPKO Health Stock Up as Q2 Earnings & Revenues Beat Estimates
OPK beats Q2 estimates as pharmaceutical growth, Nicoya income and lower costs narrow losses and lift shares pre-market.
OPKO Health, Inc. (OPK) Q2 2026 Earnings Call Transcript
OPKO Health, Inc. (OPK) Q2 2026 Earnings Call Transcript
Compared to Estimates, OPKO Health (OPK) Q2 Earnings: A Look at Key Metrics
While the top- and bottom-line numbers for OPKO Health (OPK) give a sense of how the business performed in the quarter ended June 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
OPKO Health (OPK) Reports Q2 Loss, Tops Revenue Estimates
OPKO Health (OPK) came out with a quarterly loss of $0.01 per share versus the Zacks Consensus Estimate of a loss of $0.08. This compares to a loss of $0.19 per share a year ago.
OPKO Health Q2 Earnings Call Highlights
OPKO Health NASDAQ: OPK reported a narrower second-quarter loss as gains tied to its diagnostics restructuring and a China commercialization agreement helped lift revenue, while the company continued to increase investment in clinical development programs.
OPKO Health Reports Second Quarter 2026 Business Highlights and Financial Results
MIAMI, July 27, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (OPKO) (NASDAQ: OPK), a fully-integrated healthcare company focused on delivering next-generation solutions for serious diseases across established global markets, today reports business highlights and financial results for the second quarter ended June 30, 2026. Highlights from the second quarter of 2026 and recent weeks included the following: ModeX presented data on multispecific antibody targeted in vivo CAR T cell programs at the American Society of Gene + Cell Therapy (ASGCT) Annual Meeting, with plans to enter Phase 1 studies later this year or in early 2027.
Here's Why You Should Retain OPK Stock in Your Portfolio for Now
OPKO Health's growth outlook rests on RAYALDEE, BioReference gains and partnerships, though losses and pipeline risks persist.
OPKO Health to Report Second Quarter 2026 Financial Results on July 27, 2026
MIAMI, July 23, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (OPKO) (NASDAQ: OPK), a fully-integrated healthcare company focused on delivering next-generation solutions for serious diseases across established global markets, today announced that it will report operating and financial results for the second-quarter 2026 on Monday, July 27, 2026. OPKO's senior management will host a conference call and webcast at 4:30 p.m. ET to provide a business update, discuss results and financial guidance.
OPKO Health to Report Second Quarter 2026 Financial Results on July 27, 2026
MIAMI, July 23, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (OPKO) (NASDAQ: OPK), a fully-integrated healthcare company focused on delivering next-generation solutions for serious diseases across established global markets, today announced that it will report operating and financial results for the second-quarter 2026 on Monday, July 27, 2026.
Preclinical Data for OPKO Biologics' OPK8801001 in Acromegaly Presented at ENDO 2026
MIAMI, June 15, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) OPKO Biologics, an OPKO Health company, presented preclinical data for OPK8801001 at ENDO 2026, the Endocrine Society's annual meeting. The poster, “Production and Characterization of OPK8801001, a Novel Long-Acting hGH Receptor Antagonist for the Treatment of Acromegaly,” available here, was presented by Moran Golan, Ph.D., Director of Preclinical & Clinical Pharmacology at OPKO Biologics.
OPKO Health (OPK) Up 17.1% Since Last Earnings Report: Can It Continue?
OPKO Health (OPK) reported earnings 30 days ago. What's next for the stock?
Here's Why You Should Retain OPK Stock in Your Portfolio for Now
OPKO Health leans on RAYALDEE and key partnerships, such as BioReference and 4Kscore, as it ramps toward mid-2026 diagnostics breakeven.
OPKO Health's ModeX Therapeutics Will Present Data Demonstrating In Vivo CAR-T Cell Generation and Deep B-Cell Depletion in Preclinical Studies
Multispecific antibody conjugated LNP/mRNA platform enables in vivo T-cell engineering and systemic B-cell depletion in animal models Data will be presented at the American Society of Gene & Cell Therapy (ASGCT) 2026 Annual Meeting WESTON, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- ModeX Therapeutics Inc., an OPKO Health company (NASDAQ: OPK), will announce preclinical data demonstrating the in vivo generation of CAR-T cells and deep systemic B-cell depletion achieved with its MDX3001 candidate in animal models.
OPKO Health Expands Nicoya Agreement to Support RAYALDEE® Commercialization in Greater China
MIAMI, April 30, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) (OPKO) today announced that its subsidiary EirGen Pharma Limited (EirGen) has entered into an amendment to its agreement with Nicoya Therapeutics (Macau) Limited, an affiliate of Nicoya Therapeutics (Nicoya), which grants OPKO an equity stake in Nicoya and reinforces Nicoya's commitment to commercialize RAYALDEE® in Greater China. RAYALDEE is approved in Macau, and the companies expect regulatory approvals in China and related territories in 2027.
BioReference® Launches BioReference Direct™, Expanding Access to Consumer-Initiated Diagnostic Testing Through a Fully Integrated Digital Platform
ELMWOOD PARK, N.J., April 30, 2026 (GLOBE NEWSWIRE) -- BioReference® Health LLC, an OPKO Health, Inc. company and a trusted provider of diagnostic testing in the United States, today announced the launch of BioReference DirectTM, a new digital health platform designed to give consumers direct access to high-quality laboratory testing.
OPKO Health Q1 Earnings In-Line on Product Gains, Revenues Down Y/Y
OPK's Q1 earnings match estimates as pharma product sales rose, but revenue slides 25.7% after a smaller BioReference diagnostics base.
OPKO Health, Inc. (OPK) Q1 2026 Earnings Call Transcript
OPKO Health, Inc. (OPK) Q1 2026 Earnings Call Transcript
OPKO Health (OPK) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates
Although the revenue and EPS for OPKO Health (OPK) give a sense of how its business performed in the quarter ended March 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
OPKO Health (OPK) Reports Q1 Loss, Misses Revenue Estimates
OPKO Health (OPK) came out with a quarterly loss of $0.07 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.1 per share a year ago.
Price Targets
Opko Health downgraded to Hold from Buy at Jefferies
$1.60
(was $1.46)
Jefferies
H.C. Wainwright Reiterates Buy Rating on Opko Health (OPK)
$3.00
(was $1.70)
Yi Chen
·
H.C. Wainwright
HC Wainwright & Co. Initiates Coverage On OPKO Health with Buy Rating, Announces Price Target of $3
$3.00
(was $1.29)
H.C. Wainwright
Opko Health price target lowered to $4 from $5 at Piper Sandler
$4.00
(was $2.40)
Edward Tenthoff
·
Piper Sandler